Working… Menu
Trial record 73 of 213 for:    "Hypogonadism" | "Androgens"

A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00254553
Recruitment Status : Terminated (Recruitment issues)
First Posted : November 16, 2005
Last Update Posted : December 14, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
Hypogonadal males, particularly those whose condition manifested later in life, may experience common symptoms associated with their hypogonadism. Questionnaires developed to assess these symptoms need to be tested. The primary purpose of this study is to test or validate the Patient-Reported Symptom Measure, Androgen Deficiency Quality of Life Questionnaire and the Patient Global Impression Scale.

Condition or disease Intervention/treatment Phase
Hypogonadism Drug: Testim 1% (testosterone gel) Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two Period Cross Over Trial to Validate Patient-Reported Outcome Measures for Use in Men With Late Onset Hypogonadism
Study Start Date : July 2005
Actual Primary Completion Date : January 2007
Actual Study Completion Date : January 2007

Arm Intervention/treatment
Active Comparator: Arm 1
Testim 1% (testosterone gel)
Drug: Testim 1% (testosterone gel)
Testim_ 100 mg: two tubes of 50 mg of Testim_per day
Other Name: Testim

Placebo Comparator: Arm 2
Drug: Placebo
two tubes of placebo per day

Primary Outcome Measures :
  1. Patient -reported outcome measures [ Time Frame: Baseline and after six weeks of treatment or placebo ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Men with late-onset hypogonadism who are either on testosterone treatment or naïve of treatment:

  • have symptoms of androgen deficiency at screening (after wash-out if applicable) i.e. with a positive score on the Androgen Deficiency in the Aging Male (ADAM) Questionnaire (a "yes" answer to questions 1 or 7 or any three other questions).
  • morning total T levels of <=3 ng/mL (<=300 ng/dL; <=10.4 nmol/l) on two separate days prior to randomization (after appropriate wash-out, if applicable).
  • calculated free T <=0.074 ng/mL.
  • at least 50 and at most 75 years of age.
  • BMI of at least 18 kg/m^2 or at most 32 kg/m^2

Inclusion Criteria for Normogonadal Men:

  • morning total T levels <=3 ng/mL (<=300 ng/dL; <=10.4 nmol/L).
  • calculated free T <=0.074 ng/mL.
  • at least 50 and at most 75 years of age.
  • BMI of at least 18 kg/m^2 or at most 32 kg/m^2

Exclusion Criteria:

  • History or current diagnosis of prostate cancer or any clinically significant finding on prostate examination
  • Severe obstructive symptoms of benign prostate hypertrophy
  • Prostate specific antigen (PSA) levels greater than 4 ng/mL at screening
  • History or current diagnosis of carcinoma of the breast
  • Known chronic polycythemia and/or hematocrit greater than 50% at screening
  • Treatment-naïve subjects with hyperprolactinemia at screening (serum prolactin level >=50 ng/mL)
  • Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator
  • clinically significant abnormal physical finding prior to randomization
  • sensitive to trial medication or its components
  • History or presence of hepatic or renal disorder considered as clinically relevant in the opinion of the investigator.

Exclusion Criteria for Normogonadal Men:

  • Presence or previous diagnosis of androgen deficiency.
  • Previous or present use of testosterone preparations
  • Use of medication within the 12 weeks prior to the visit that may interfere with the objectives of the trial: hypothalamic/pituitary hormones and analogues (e.g., gonadotropins, ACTH, STH, Gn-RH agonists and antagonists, etc.); sex steroid
  • Any other disease that in the opinion of the investigator might compromise or confound the subject's symptomatology (e.g., presence of clinically significant depression or other psychiatric disorders, unstable endocrine disorder, sleep apnea, cardiovascular and cerebrovascular diseases, etc.)

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00254553     History of Changes
Other Study ID Numbers: P05815
First Posted: November 16, 2005    Key Record Dates
Last Update Posted: December 14, 2015
Last Verified: December 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents